Controlled human malaria infection (Q40205689)

18 September 2017

Controlled human malaria infection (English)

1 reference

18 September 2017

0 references

Christian F Ockenhouse

series ordinal

3

object named as

Christian Ockenhouse

1 reference

18 September 2017

1

Michele Spring

1 reference

18 September 2017

Mark Polhemus

2

1 reference

PubMed ID

24872394

18 September 2017

language of work or name

English

0 references

publication date

1 June 2014

1 reference

Journal of Infectious Diseases

18 September 2017

1 reference

18 September 2017

209 Suppl 2

1 reference

18 September 2017

S40-5

1 reference

A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection

18 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Human malaria parasites in continuous culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Controlled human blood stage malaria infection: current status and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

From the circumsporozoite protein to the RTS, S/AS candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

The RTS,S vaccine candidate for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Experimental human challenge infections can accelerate clinical malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Taking a bite out of malaria: controlled human malaria infection by needle and syringe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

Human microbial challenge: the ultimate animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU063

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIU063

1 reference

18 September 2017

1 reference

PubMed ID

24872394